Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development

BJU Int. 2005 Aug;96(3):286-90. doi: 10.1111/j.1464-410X.2005.05616.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review
  • Retracted Publication

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use
  • Benzenesulfonates / therapeutic use
  • Bevacizumab
  • Carcinoma, Renal Cell / metabolism
  • Carcinoma, Renal Cell / therapy*
  • Clinical Trials as Topic
  • Humans
  • Indoles / therapeutic use
  • Kidney Neoplasms / metabolism
  • Kidney Neoplasms / therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use
  • Pyrroles / therapeutic use
  • Sorafenib
  • Sunitinib
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • Sunitinib